Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04995029 · ClinicalTrials.gov registry record · Phase 4
Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users
A Phase 4 study, sponsored by Indivior.
- Completed
- Registry status
- Phase 4
- Development phase
- 785
- Enrollment target
NCT04995029 is a Phase 4 study that has completed, run by Indivior. The registered enrollment target is 785 participants.
The verdict
NCT04995029, a Phase 4 study, has completed, sponsored by Indivior.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 785 participants
- Enrollment target
Study Summary
The primary objective of the induction phase of the study is to compare treatment retention of participants following rapid induction or standard of care (SoC) induction onto extended-release buprenorphine. The primary objective of the maintenance phase is to compare the efficacy of 100 mg and 300 mg maintenance doses of extended-release buprenorphine administered every 4 weeks.
Interventions
- DRUG Extended-release Buprenorphine
- DRUG Transmucosal Buprenorphine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 785 participants |
| Start Date | 2021-10-26 |
| Est. Completion | 2024-06-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04995029
The ClinicalTrials.gov registry entry for NCT04995029 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 785 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indivior, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Extended-release Buprenorphine is the first listed.
NCT04995029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04995029 about?
NCT04995029 is a clinical study titled "Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users". The primary objective of the induction phase of the study is to compare treatment retention of participants following rapid induction or standard of care (SoC) induction onto extended-release buprenorphine. The primary objective of the maintenance phase is to compare the efficacy of 100 mg and 300 ...
What is the current status of trial NCT04995029?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 785 participants. The study started on 2021-10-26. Estimated completion is 2024-06-26.
What interventions are being tested in trial NCT04995029?
The interventions under investigation include: Extended-release Buprenorphine (DRUG), Transmucosal Buprenorphine (DRUG).
Who is sponsoring clinical trial NCT04995029?
This trial is sponsored by Indivior, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.